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ABSTRACT:
Cancer remains one of the major cause of death in the Western world. Although, 
it has been demonstrated that new therapies can improve the outcome of cancer 
patients, still many patients relapse after treatment. Therefore, there is a need to 
identify novel factors involved in cancer development and/or progression. Recently, 
neutrophil gelatinase-associated lipocalin (NGAL) has been suggested as a key player 
in different cancer types. Its oncogenic effect may be related to the complex NGAL/
MMP-9. In the present study, NGAL was analyzed at both transcript and protein levels 
in different cancer types by analysing 38 public available microarray datasets and 
the Human Protein Atlas tool. 
NGAL transcripts were significantly higher in the majority of solid tumors 
compared to the relative normal tissues for every dataset analyzed. Furthermore, 
concordance of NGAL at both mRNA and protein levels was observed for 6 cancer 
types including bladder, colorectal, liver, lung, ovarian, and pancreatic. All metastatic 
tumors showed a decrease of NGAL expression when compared to matched primary 
lesions. 
According to these results, NGAL is a candidate marker for tumor growth in a 
fraction of solid tumors. Further investigations are required to elucidate the function 
of NGAL in tumor development and metastatic processes.
INTRODUCTION 
Metastatic spreading is the major cause of death 
in cancer patients. Several molecules have been shown 
to contribute to tumor invasion and spreading. In this 
manuscript the roles of neutrophil gelatinase-associated 
lipocalin (NGAL) in cancer development and progression 
are described.  
Members of the lipocalin protein family are 
characterized by their ability to bind small hydrophobic 
molecules (such as prostaglandins, retinoids, arachidonic 
acid, hormones and fatty acids). They often bind to 
specific cell-surface receptors and form macromolecular 
complexes. Highly conserved lipocalin crystal structures 
consist of a single eight-stranded continuously hydrogen-
bonded antiparallel β-barrel delineating a calyx shape, 
which represents the internal ligand-binding site (Figure 
1). Members of the lipocalin family, in the past classified 
exclusively as transport proteins, have now been described 
to carry out a variety of different functions. Some of these 
functions include: retinol transport, cryptic coloration, 
olfaction, pheromone transport, and the enzymatic 
synthesis of prostaglandins, moreover the lipocalins are 
also involved in the regulation of the immunoresponse and 
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the mediation of cell homoeostasis [1]. 
NGAL, also called lipocalin 2 siderocalin and 
24p3, was identified in several forms: a monomer (25-
kDa), a disulfide-linked homodimer (46-kDa), and a 
disulfide-linked heterodimer with human neutrophil 
gelatinase B (135-kDa) [2]. NGAL has several functions. 
In early studies NGAL was described as a factor of innate 
immune system. NGAL is released by neutrophils at 
sites of infection and inflammation to sequester bacterial 
ferric siderophores, participating in the antibacterial 
iron-depletion strategy of innate immune system [3]. 
Subsequently, it was shown that NGAL is responsible for 
iron delivery to the cytoplasm where it is accumulated 
and activates or represses iron-responsive genes. Iron 
unloading depends on the cycling of NGAL through 
acidic endosomes [4]. In contrast, Devireddy LR et al have 
shown that NGAL is also involved in apoptosis-dependent 
deprivation of trophic factors. Apo-NGAL, after binding to 
its putative receptor, 24p3R, is internalized and associates 
with an intracellular siderophore, transferring chelated iron 
to the extracellular medium, thereby reducing intracellular 
iron concentration which leads to the expression of the 
pro-apoptotic protein Bim, leading to the induction of 
apoptosis [5].
NGAL was originally identified as a protein 
covalently associated with 92-kDa gelatinase/MMP9 from 
human activated neutrophils [2]. NGAL is expressed  in 
many other types of cells in response to various injuries, 
especially in kidney diseases. Serum NGAL levels 
correlate clearly with the severity of renal injury, reflecting 
the degree of tissue damage. For this reason, NGAL 
may become one of the most promising next-generation 
biomarkers in clinical nephrology and as well as other 
diseases and pathological states [6]. 
NGAL is up-regulated by IL-1 beta, but not by TNF-
alpha, in type II pneumocyte-derived cell line through the 
induction of the NF-kB pathway [7]. IL-1 beta selectivity 
in inducing NGAL is due to the synthesis of  IkB-zeta, a 
NF-kB-binding cofactor, elicited specifically by IL-1beta 
stimulation which is required for transcriptional activation 
of NGAL [8]. Stimulation with TNF-alpha in the presence 
of IL-17, which stabilizes the IkB-zeta transcript, is able 
to induce NGAL expression by IkB-zeta protein binding 
to NF-kB on the NGAL promoter [9]. It has been also 
demonstrated that activation of the NF-kB pathway is 
associated with up-regulation of NGAL-ErbB2-mediated 
signaling [10] (Figure 2).
NGAL’s ability to combine in a dimeric complex 
with MMP-9, results in a protective action of MMP-9 from 
its auto-degradation and consequently results in a higher 
gelatinolytic action of MMP-9 on extracellular matrix 
[11]. By this function, it has been shown that NGAL may 
promote cancer development in a variety of different 
cancer types [12-15] (Figure 2). Conversely, anticancer 
activities of NGAL have been demonstrated by its ability 
to inhibit the pro-neoplastic factor HIF-1a, the synthesis of 
HIF-1a-dependent VEGF [16,17], and phosphorylation of 
FAK kinase [17], as shown in colon [18], ovarian [19] and 
pancreatic [17] cancers.
Further evidences indicate that NGAL plays key 
roles in the inflammation and in the regulation of cell 
growth and adhesion in both normal and tumor tissues 
[20-23]. 
In the present study, NGAL transcript levels and its 
potential clinical implications in different cancer types 
were examined by bioinformatic approaches. NGAL 
transcript levels were explored in different cancer types 
by analysing public available microarray datasets. Further 
evaluation of NGAL protein expression were performed 
by analyzing the Human Protein Atlas. According to both 
the results of the present analyses and previous published 
data, NGAL potential clinical implications are also 
discussed.  
RESULTS 
mRNA expression of NGAL in different tumor 
types
Gene expression patterns of NGAL mRNAs present 
in different tumor types were obtained from several 
datasets (Table 1). Significant differences between tumor 
tissues and relative normal counterparts for each cancer 
type are reported in Table 1. This analysis showed that 
NGAL transcript levels were significantly higher in the 
majority of solid tumors compared to the relative normal 
tissues for every dataset analyzed. While, lower levels 
of NGAL were observed in each dataset of cervical 
Figure 1: Highly conserved lipocalin crystal structures 
consist of a single eight-stranded continuously 
hydrogen-bonded antiparallel β-barrel (A) delineating 
a calyx shape, which represents the internal ligand-
binding site (B). Hydrophobicity surface (C). Images were 
created from the RCSB PDB database (http://www.rcsb.org) 
(ID: 1NGL) using the UCSF Chimera package UFCS Chimera 
package that is developed by the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, 
San Francisco (supported by NIGMS P41-GM103311). Ref: The 
solution structure and dynamics of human neutrophil gelatinase-
associated lipocalin by Coles M, et al. J Mol Biol. 1999; 289: 
139-57. 
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Table 1: Gene expression patterns of NGAL in different cancer types from 29 datasets
Cancer Type
# of samples Fold Change
(≤-2) or (≥2) 
p < 0.01 
(T-test)
Dataset
Cancer Normal Author [Ref.] Year Platform
Solid tumor
Bladder 109 48 4.13 2.75E-05 Sanchez-Carbayo M [86] 2006 U133A
Cervix 32a 24 -3.21 4.06E-04 Scotto L [87] 2008 U133A
Colon  
95 5 2.62 1.23E-02 Kaiser S [88] 2007 U133 Plus 2.0
81 24 4.15 7.04E-08 Skrzypczak M [89] 2010 U133 Plus 2.0
70 12 4.78 7.06E-06 Hong Y [90] 2010 U133 Plus 2.0
Esophagus
17b 17 -5.41 9.27E-05 Hu N [91] 2010 U133A
53b 53 -2.92 1.05E-06 Su H [92] 2011 U133A/B
Head and Neck 
6d 4 -18.58 7.33E-03 Schlingemann J [93] 2005 U133A
31c 10 -12.44 3.60E-09 Sengupta S [94] 2006 U133 Plus 2.0
kidney 51e 5 4.15 4.98E-05 Yusenko MV [95] 2009 U133 Plus 2.0
Liver
35 10 8.66 2.32E-05 Wurmbach E [96] 2007 U133 Plus 2.0
22 21 3.48 5.14E-04 Roessler S (1) [97] 2010 U133 Plus 2.0
225 220 2.94 6.86E-22 Roessler S (2) [97] 2010 HT U133A
Lung 30f 30 2.79 1.72E-03 Su LJ [98] 2007 U133A
58f 49 2.28 2.64E-06 Landi MT [99] 2008 U133A
226f 20 3.707 1.53E-7 Okayama H [100] 2012 U133 Plus 2.0
Ovary
185g 10 5.84 1.54E-06 Bonome T [101] 2008 U133A
99g 4 3.03 6.98E-04 Hendrix ND [102] 2006 U133A
Pancreas
36h 16 14.05 5.15E-06 Pei H [103] 2009 U133 Plus 2.0
11h 6 10.00 9.03E-05 Segara D [104] 2005 U133A
39i 39 7.70 1.64E-10 Badea L [105] 2008 U133 Plus 2.0
Thyroid 9
j 9 3.77 9.76E-4 He H [106] 2005 U133 Plus 2.0
14j 4 2.33 0.001 Vasko V [107] 2007 U133 Plus 2.0
26j 4 2.05 9.34E-7 Giordano TJ [108] 2006 U133A
Hematologic tumor
ALL 750 74 -11.77 7.57E-152 Haferlach T [109] 2010 U133 Plus 2.0
AML 542 74 -16.94 2.32E-165 Haferlach T [109] 2010 U133 Plus 2.0
285 8 -4.91 5.00E-03 Valk PJ [110] 2004 U133A
CLL 448 74 -42.98 7.73E-194 Haferlach T [109] 2010 U133 Plus 2.0
Myeloma 9k 5 -3.90 0.002 Agnelli L [111] 2009 U133A
Legend: Solid tumor: Cervix: aCervical Squamous Cell Carcinoma. Esophagus: bEsophageal Scquamous Cell Carcinoma; Head and Neck: 
cNasopharyngeal Carcinoma; dSquamous Cell Carcinoma. Kidney: eRenal Carcinoma; Liver: (1), dataset 1; (2) dataset 2; Lung: fLung 
adenocarcinoma; Ovary: gOvarian Carcinoma; Pancreas: hPancreatic Carcinoma; iPancreatic Ductal Adenocarcinoma; Thyroid: jThyroid 
Gland Papillary Carcinoma
Hematologic tumor: ALL, Acute Lymphoblastic Leukemia; AML, Acute Myeloid Leukemia; CLL, Chronic Lymphocytic Leukemia. 
Myeloma: kPlasma Cell Leukemia. 
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Table 2: NGAL transcripts in metastatic tissues compared to the relative primary tumor
Cancer Type
# of samples FC (≤ -1.5) or 
(≥ 1.5)
p < 0,05 (T-test)
Data set
metastasis primary Author [Ref.] Year Platform
Colorectal 43 330 -3.191 1.56E-06 Bittner M[a] 2005 U133 Plus 2.0
27 56 -5.437 1.04E-06 Tsuji S [112] 2012 U133 Plus 2.0
Kidney 60 9 -1.960 4.00E-03 Jones J [113] 2005 U133A
Melanoma
40 16 -2.475 3.00E-03 Riker AI [114] 2007 U133 Plus 2.0
52 31 -4.849 1.12E-08 Xu L [115] 2008 U133A
Ovarian
75 166 -1.999 2.00E-03 Bittner M[a]  2005 U133 Plus 2.0
16 74 -1.537 4.30E-03 Anglesio MS [116] 2008 U133 Plus 2.0
Prostate 5 27 -1.578 2.60E-02 Vanaja DK [117] 2003 U133A/B
6 7 -5.735 7.76E-04 Varambally S [118] 2005 U133 Plus 2.0
[a] GEO Series GSE2109; FC, Fold change
Figure 2: Effects of NGAL on survival, motility, angiogenic, apoptotic and glucose metabolism. NGAL: neutrophil 
gelatinase-associated lipocalin; MMP9: matrix metalloproteinase 9; NGAL-R: NGAL receptor; ErbB-2: v-Erb-B2 Avian Erythroblastic 
Leukemia Viral Oncogene Homolog = HER2; TNF-α: Tumor Necrosis Factor Alpha; IL-17: interleukin-17; IL-1β: interleukin-1 beta; FAK: 
focal adhesion kinase; NF-κB: nuclear factor kappa B cells; IκBζ: Inhibitor of NF-κB zeta subunit; HIF-1α: hypoxia inducible factor 1 
alpha; VEGF: vascular endothelial growth factor. Fe++: Ferrous iron; Green lines with arrows indicate activation of pathway, red lines with 
blocked ends indicate inhibition of pathway, blue lines indicate transcriptional activation and additional events.
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cancer, esophageal cancer, head and neck cancer and in 
haematological malignancies. In Table 2 are presented 
the significant differences of NGAL transcript levels 
observed in metastatic tissues compared to those of the 
relative primary tumor. The results showed that in all 
dataset analyzed the levels were significantly lower in the 
metastatic tissues than in primary tumors from 5 different 
tumor types, including colorectal, kidney, melanoma, 
ovarian and prostate (Table 2). 
In Figure 3 the distribution of NGAL transcript 
levels among cancer cases and normal samples is shown. 
The percentage of tumor cases showing NGAL transcript 
levels below the 25th percentile and above the 75th 
percentile of the “normal” samples is also reported.   
Protein expression of NGAL in different tumor 
types   
To understand if there was an association 
between mRNA and protein NGAL expression, an 
immunohistochemistry evaluation was performed by 
analysis of Human Protein Atlas web site. In Figure 4 
immunohistochemistry analysis of NGAL in 15 solid 
cancer types are shown. Cancer types with negative 
immunostaining are not shown. The data demonstrated 
Figure 3: Distribution of NGAL transcript levels among cancer cases and normal samples. The percentage of tumor cases, 
indicated for each tumor setting, shows NGAL transcript levels below the 25th percentile (Cyan box) and above the 75th percentile (Magenta 
box) of the “normal” samples.   
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that concordance of NGAL at both mRNA and protein 
levels was obtained for the following cancer types: 
bladder, colorectal, liver, lung, ovarian, and pancreatic 
(Table 1 and Figure 4, Panels: A, E, I, J, H and L). 
Cervical, esophageal/stomach and head and neck cancers 
showed a moderate positive immunostaining (Figure 4, 
panel D, F and G), while mRNA expression levels were 
lower in cancer tissue compared to the normal counterpart 
(Table, 1). 
Conversely, weak immunostaining (<10% of cases) 
or negative protein expression levels were observed in 
brain, breast, melanoma and prostate cancers. Accordingly, 
no significant differences in NGAL mRNA expression 
were observed between cancer and relative normal 
counterpart in all datasets analysed for each of these 
4 cancer types (brain, breast, melanoma and prostate) 
(Figure 4, Panel B, C, K and M). 
Although, higher mRNA levels were detected 
in renal and thyroid cancers than in relative normal 
counterparts (Table 1), a negative immunostaining was 
Figure 4: Immunohistochemistry analysis of NGAL expression in human cancer. The data were obtained from the Human 
Protein Atlas. A single representative case for each cancer type (total 15) is shown along with its normal counterpart. Expression of NGAL 
in cancer sample was evaluated as strong, moderate, weak and negative immunostaining. The percentage is referred to the total cancer 
samples analyzed for each tumor type. 
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Table 3: Clinical impact of NGAL expression pattern in different cancer type according to previous studies
TUMOR TYPE METHODS CLINICAL IMPACT OF NGAL EXPRESSION AUTHOR [REF.]
SOLID TUMORS
BLADDER 
CM, GZ ,MS Diagnostic marker Roy R [24]
Monier F [25]
GZ, IHC, 
ELISA Early marker of tumor progression Monier F [26]
BRAIN 
IHC, GZ, 
ELISA Diagnostic marker Smith [15]
IHC
Positive correlation with high proliferation index in 
primary tumor Barresi [28]
IHC Associated with poor outcome Liu MF [27]
BREAST 
IHC Associated with poor outcome Stoesz SP [29]
ELISA Positive correlation with lymphatic node metastasis Shen ZZ [31]
ELISA Positive correlation with breast cancer aggressiveness Provatopoulou X [32]
IHC
Positive correlation with poor prognosis in primary 
human breast cancer Bauer M [30]
IHC Positive correlation with poor outcome Li [10]
IHC Positive correlation with poor outcome Wenners [38]
CERVICAL IHC Positive correlation with HPV type Syrjänen [39]
COLORECTAL 
IHC, FISH Positive correlation with tumor trasformation Nielsen [40]
ELISA Prognostic utility in metastatic patients Martì [44, 45]
PCR, GZ Diagnostic marker Catalan [43]
ELISA Not suitable as a diagnostic marker Fung KY [46]
ELISA Not useful marker of progression McLean MH [47]
ESOPHAGEAL GZ, IHC,  WB Positive correlation to cancer differentiation Zhang [14]
IHC Positive correlation with progression Du ZP [49]
GASTRIC 
IHC, ELISA, 
WB Positive correlation with poor outcome Kubben [13]
IHC, ELISA
Diagnostic marker and positive correlation with poor 
outcome Wang HJ [60]
HEAD & NECK ELISA Positive correlation with poor outcome Lin CW [61]
HCC IHC Positive correlation with poor outcome Zhang Y [62]
LUNG IHC Positive correlation with poor outcome Friedl A [20]
PANCREATIC ELISA Diagnostic marker Moniaux N [71]
OVARIAN 
IHC, ELISA, 
WB Promotion of epithelial to mesenchymal transition Lim R [19]
PCR, IHC, 
ELISA Positive correlation to cancer differentiation Cho [65]
RENAL IHC Positive correlation with malignant phenotype Barresi [76]ELISA Positive correlation with poor outcome Porta [77]
THYROID IHC, Real time Positive correlation with malignant phenotype Iannetti [81]
IHC Diagnostic marker Barresi [79, 80]
HEMATOLOGICAL 
MALIGNANCIES 
AML RT-PCR Positive correlation with better prognosis Yang WC [82]
CML RT-PCR
Positive correlation with early stage of disease and
BCR-ABL positivity
Villalva C [84]
AML, Acute Myeloid Leukemia, CM,  Chromatography; CML, Chronic Myelogenous Leukemia; GZ, Gel zymography;  HCC, 
Hepatocellular Carcinoma; IHC, Immunohistochemistry. MS, Mass Spectrometry.
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observed (Figure 4, Panel H and N). Finally, concordant 
negative mRNA and protein levels of NGAL were 
observed in the majority of haematological malignancies 
(data not shown).  
Clinical impact of different NGAL expression 
pattern 
To further understand if different NGAL expression 
pattern may affect the clinical behaviour of several cancer 
types, an analysis of previously published studies was 
performed and is summarized in Table 3.  
DISCUSSION
Until now, NGAL has been investigated primarily as 
an inflammatory factor and as a marker of kidney damage 
[6]. However, recent studies have indicated that NGAL 
has potential roles in cancer development and NGAL may 
have pro-oncogenic or anti-oncogenic functions [22]. In 
fact, its oncogenic effect is related to the complex NGAL/
MMP-9 [11]; while its anti-tumor effect is related to the 
inhibition of the pro-neoplastic factor HIF-1a, the HIF-
1a-dependent VEGF and FAK [16, 17]. In the present 
study, computational and IHC evaluations were performed 
to understand whether differences in NGAL transcript 
or protein levels occur in different cancer types when 
compared with the relative normal tissues or the metastatic 
counterparts. The results obtained for each tumor type 




The current study reveals that both mRNA transcript 
and protein levels were higher in bladder cancer tissues 
than in the normal counterparts. Accordingly, 50.5% of 
cases displayed NGAL transcripts above the 75th percentile 
of the “normal” values suggesting its role as a diagnostic 
marker. These data are in agreement with previous 
investigations in which NGAL along with MMP-9 were 
overexpressed in urothelial bladder carcinomas suggesting 
their role as early diagnostic markers for this tumor type 
[24, 25]. Reduced protein levels of both NGAL and MMP-
9 have been detected in urine samples from bladder cancer 
patients with clinical relapse suggesting that reduced 
levels of these proteins may be used as indicators of tumor 
progression [26].
Brain 
A significant association of MMPs and NGAL 
expression was detected in urine from brain cancer patients 
and in tumor specimens. Additionally, surgical resection 
of the tumor resulted in a reduction of both MMPs and 
NGAL in urine samples [15]. The identification of new 
potential molecular targets in this cancer type may be 
very helpful to discover new therapeutic strategies. 
Immunohistochemistry analysis reveals that NGAL 
expression is frequently up-regulated in gliomas and is 
associated with poor clinical outcome [27]. Barresi et 
al show that NGAL was overexpressed in primary high 
grade brain tumors and not in the metastatic cases [28]. 
According to the exclusion criteria designed for the 
purpose of our present study, no data on brain cancer were 
generated by computational analysis. Accordingly, NGAL 
protein expression was not detected through the Human 
Protein Atlas evaluation. 
Breast
Similar observations acquired for brain tumors 
were obtained for breast cancer as no data were generated 
by our computational analysis. The expression pattern 
of NGAL has been evaluated by several authors and 
generated conflicting results on the clinical significance of 
this protein in breast cancer. 
A heterogeneous pattern of expression at the mRNA 
and protein levels was observed in breast cancer patients 
in a study conducted by Stoesz SP et al [29]. The authors 
also described a significant correlation between NGAL 
expression and other markers of poor prognosis, including 
estrogen and progesterone receptor-negative status and 
high proliferation (S-phase fraction) [29]. These studies 
were also confirmed by Bauer M et al [30]. Similarly, 
Shen ZZ et al showed that MMP-9 and MMP-9/NGAL 
complex expression were higher in breast cancer than 
in benign breast and/or normal tissues [31]. While, in 
the study conducted by Provatopoulou X et al. in a large 
series of breast cancer patients, MMP-9 and NGAL were 
overexpressed in cancer and this overexpression was 
associated with the severity of disease but no significant 
correlation was found for the complex formation [32].
In a transgenic mouse model of breast cancer, Berger 
et al. demonstrated that lack of NGAL in mice leads to a 
reduction of tumor growth. This reduction was attributed 
to an NGAL-dependent decrease of MMP-9 activity and 
to a lack of high molecular weight MMP activity [33]. 
Accordingly, Li et al have shown that NGAL expression 
is associated with increased metastasis and poor prognosis 
in breast cancer patients [10]. The results obtained by 
Leng et al in an animal model of breast cancer suggest 
that the suppression of NGAL function, by an inhibitory 
monoclonal antibody, has a great potential for breast 
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cancer therapy, particularly by interfering with metastasis 
in aggressive types of breast cancer [34]. Conversely, in a 
previous study it was shown that NGAL overexpression 
promotes in vivo the development of lung metastasis. 
[35]. Our recent studies indicate that increased NGAL 
expression did not alter the sensitivity of the MCF-7 breast 
cancer cell line to the chemotherapeutic drug doxorubicin 
[36]. However, ectopic NGAL expression did alter the 
sensitivity of breast cancer cells to targeted therapy [37]. 
Furthermore, NGAL was found to be a predictive marker 
for complete response after neo-adjiuvant chemotherapy 
in low-risk subgroups of breast cancer patients and may 
be considered as an independent prognostic factor for 
decreased disease free survival in primary human breast 
cancer [38]. 
Cervical cancer
A recent analysis conducted by 
immunohistochemistry on a set of cervical biopsy 
specimens from 225 women showed a close relationship 
between NGAL expression levels, HPV lesion grade and 
detection of high risk HPV types. Up-regulation of NGAL 
in higher grade lesions is likely to from the suppression of 
wild-type p53 by the HPV E6 oncoprotein. Suppression 
of p53 results in elimination of p53 block of NGAL 
transcription [39]. These data were in agreement with our 
IHC evaluation but not in line with our computational 
analysis as only 6.3% of cervical cases displayed NGAL 
transcripts above the 75th percentile of “normal” values, 
while 59.4% below the 25th percentile.  
Colorectal cancer
In 1996 Nielsen et al analysed the role of NGAL 
by both immunohistochemistry and mRNA by in situ 
hybridization in colon cancer and in inflammatory 
colorectal diseases. Increased expression of NGAL 
was detected both in non-malignant epithelium such 
as diverticulitis, inflammatory bowel disease and in 
malignant colonic lesions. In adenocarcinomas, NGAL 
overexpression was observed in the transitional mucosa 
and in the superficial ulcerated area. On the other hand, 
NGAL expression was not detected in lymph node 
metastases from this adenocarcinoma [40]. The authors 
speculate that NGAL is predominantly involved in 
inflammatory reaction and in tumor transformation, while 
it does not appear to play a prominent role in metastatic 
process. 
However, Lee et al have shown that NGAL may 
function as a metastasis suppressor in colon cancer cells. 
In their studies, they genetically manipulated highly 
metastatic human colon cancer cell lines, which normally 
express low NGAL protein levels, to overexpress NGAL. 
Ectopic expression of NGAL suppressed, in vivo, the liver 
metastasis of metastatic human colon cancer cell lines in 
experimentally-driven metastasis assays [18]. Hu et al 
examined the potential molecular mechanism of NGAL 
involvement in colorectal cancer. They demonstrated that 
NGAL overexpression altered the subcellular localization 
of E-cadherin and catenins, decreased E-cadherin-
mediated cell to cell adhesion, enhanced cell–matrix 
attachment, and increased cell motility and in vitro 
invasion. They proposed that NGAL exerted these effects 
through the alteration of the subcellular localization 
of Rac1, one of Rho small GTPases, in an extracellular 
matrix-dependent manner, but not by MMP-9 [41]. 
Recently, Bousserouel S et al have shown, in a preclinical 
model of colon carcinogenesis, that NGAL is significantly 
upregulated only in advanced stages of tumor progression 
[42].
Real time PCR and zymographic analysis  on 
visceral adipose tissue (VAT) biopsies from 11 colon 
cancer patients revealed increased levels of NGAL and 
other inflammation associated factors like osteopontin, 
tumor necrosis factor-α (TNF-α), and chitinase-3 like-1 
compared to control subjects, suggesting their involvement 
in cancer development and progression [43].
Recently, Martí J et al showed the prognostic 
utility of NGAL mainly in metastatic CRC [44, 45]. 
Higher levels in colon cancer cases then controls were 
observed by Fung KY et al but the authors concluded 
that it was not a promising biomarker for the diagnosis 
of CRC as the sensitivity of NGAL was found to be 24% 
at 90% specificity [46]. Accordingly, although NGAL 
is still expressed by the majority of human neoplastic 
colorectal lesions, the author it is not a useful biomarker 
for determining disease progression from adenomatous 
to malignant colorectal neoplasia [47]. Our analysis, 
in line with the majority of previous studies, shows the 
upregulation of NGAL in adenocarcinoma tumor samples 
and reduced expression in metastatic samples.  
Esophageal cancer 
Esophageal cancer is the eighth most common 
incident cancer in the world and ranks sixth among all 
cancers in mortality. Esophageal cancers are classified 
into two histological types; esophageal squamous 
cell carcinoma (ESCC), and adenocarcinoma, and the 
incidences of these types show a striking variety of 
geographic distribution, possibly reflecting differences in 
exposure to specific environmental factors. Both alcohol 
consumption and cigarette smoking are major risk factors 
for the development of ESCC [48].
Zhang et al performed immunohistochemistry, 
western blot and gelatin zymography on 81 paraffin 
sections including ESCC, normal mucosa, simple 
hyperplasia and dysplasia, and on 73 fresh specimens 
of ESCC to evaluate the role of NGAL in ESCC. 
Immunohistochemical studies revealed that ESCC have a 
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diverse and obvious whole-cytoplasmic staining pattern for 
NGAL, while normal oesophageal epithelium presented 
a weak positive signal within a restricted cytoplasmic 
area. On western blot analysis, NGAL expression level 
was found to be significantly higher in ESCC than in 
normal mucosa, and positively correlated with cancer cell 
differentiation. No significant association was observed 
between NGAL expression and cell proliferation. Finally, 
the authors showed higher enzymatic activity of NGAL/
MMP-9 complex in ESCC than in normal mucosa. These 
findings suggest that NGAL is involved in differentiation 
pathways and invasive progression of ESCC [14]. Similar 
data were reached by Du et al, [49]. Accordingly our 
IHC evaluations show that NGAL is overexpressed in 
tumor and not in normal tissue. However, different trend 
is observed by analyzing the transcript levels as 71.4% 
of cases displayed NGAL transcripts below the 25th 
percentile of “normal” values, while 8.6% above the 75th 
percentile.  
Fang et al. identified a new NGALR isoform 
designated as NGALR-3, that results from alternative 
splicing. Interestingly, it was shown that the NGALR-3 
isoform was overexpressed in 70% of esophageal 
carcinoma cases in comparison with those of normal 
adjacent epithelium. These findings suggest that the new 
NGALR-3 variant could play a more important role in 
esophageal carcinoma. The authors proposed that the novel 
NGALR-3 isoform could mediate a unilateral intracellular 
iron-delivery pathway which increased intracellular iron 
levels. This could be involved in the tumor growth of 
esophageal carcinomas [50]. 
Li EM et al studied the role of NGAL in invasion, 
division and proliferation of an esophageal carcinoma cell 
line. Their results demonstrated that the antisense blocking 
of NGAL transcription not only decreased effectively the 
activity of MMP-9 and MMP-2 secreted by SHEEC cells, 
but also suppressed significantly the invasion of these cells 
in nude mice. However, it was shown that NGAL was 
not apparently related with division and proliferation of 
SHEEC tumor cells [51]. Furthermore, the same authors, 
in attempt to demonstrate the regulation mechanism of 
NGAL overexpression in SHEEC, analyzed the structural 
characters of 5’-untranslated region(5’-UTR) and 
3’untranslated region (3’-UTR) of NGAL. Upon cloning 
and DNA sequencing of  69 bp 5’-UTR and 147 bp 3’-
UTR of NGAL gene they did not observe any base pair 
mutations [52].
Gastric cancer
Gastric cancer (GC) is the final result of a multistep 
process initiated by environmental factors, including 
diet and Helicobacter pylori infection [53]. H. pylori 
infection is one of the most important risk factors for this 
malignancy [54, 55]. 
During infection, H. pylori synthesize siderophores, 
which chelate Fe3+ with high affinity and facilitate its 
transport into the pathogen [56-58]. The host cells respond 
to infection by increasing the secretion of NGAL that 
binds the bacterial siderophores and prevents their uptake 
into bacteria. The iron depletion results in inhibiting H. 
pylori growth [59]. 
NGAL and NGAL/MMP9 complex were shown to 
be upregulated in GC tissue (mainly in neutrophils and 
epithelial cells) compared to adjacent normal gastric 
mucosa, confirming the hypothesis that the association 
of NGAL with MMP9 could prevent extracellular 
autodegradation of the proteinase. Enhanced levels of 
the NGAL/MMP9 complex, but not of MMP-9 and 
lipocalin-2, have been related to worse clinical outcome 
in cancer patients and significantly associated with the 
classifications of Lauren and WHO, suggesting that 
NGAL/MMP9 complex could be considered as a novel 
prognostic factor for gastric cancer [13].
Wang HJ et al [60] proposed NGAL as a potential 
biomarker for prognosis and an ancillary diagnostic 
test of gastric cancer. In this study, they showed high 
levels of NGAL expression in 333 GC patients by 
immunohistochemistry. NGAL was correlated with size 
of tumor, Lauren’s classification, lymph node metastasis, 
vascular invasion, distant metastasis and TNM stage. The 
multivariate analysis indicated that NGAL can be used 
as an independent prognostic factor. Serum NGAL levels 
were determined in blood samples from 63 healthy donors 
and 60 GC patients and analysed according to TNM. 
NGAL blood levels were higher than those of CA19-9 in 
TNM I patients, and higher than those of CEA and CA19-
9 in TNM II. Therefore, serum NGAL has a great potential 
as a tumor marker for GC and could be associated with a 
poor prognosis [60]. 
According to the exclusion criteria designed for 
the purpose of our present study, no data on GC were 
generated by our analyses.
Head and neck
Our “in silico” analysis showed a significant down-
regulation of NGAL in head and neck cancer compared 
to the normal counterpart. In fact, 94.6% of head and 
neck cancer displayed NGAL transcripts below the 
25th percentile of “normal” values, while no samples 
showed mRNA levels of NGAL above the 75th percentile. 
However, our IHC evaluation is in line with previous data 
[61] as expression of NGAL appeared to be moderate in 
50% of cases and absent in normal tissue. 
Hepatocellular Carcinoma (HCC)
Zhang Y et al demonstrated the up-regulation of 
NGAL expression in HCC was significantly correlated 
with unfavourable clinic-pathologic features and 
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independent poor prognostic factor for overall survival 
in patients [62]. In agreement, our analysis showed a 
significant up-regulation of NGAL mRNA levels in HCC 
from 2.3- to 8.6-fold changes in comparison to normal 
hepatic tissues in the three datasets analyzed. Similar data 
were obtained by IHC considerations. 
Lung cancer
At the present, few studies have been performed to 
evaluate the role of NGAL in lung cancer. However, Friedl 
A et al found high NGAL levels in lung adenocarcinoma 
[20]. Accordingly, in the present study we detected a 
constant NGAL upregulation both at mRNA and protein 
levels for adenocarcinoma histotype. In contrast, NGAL 
was not overexpressed in carcinoid lung cancer.
Melanoma
In melanoma a substantial down-regulation of 
NGAL was observed only in metastatic disease versus 
primary tumor while no statistic differences were 
observed in NGAL mRNA levels between primary tumor 
and normal tissue. Protein expression of NGAL was not 
detected by IHC (Human Protein Atlas web site) (Figure 
4, Panel K). To our knowledge no previous data were 
generated on NGAL in melanoma tissue samples.  
Ovarian cancer 
Epithelial ovarian cancer is one of the most 
aggressive cancers diagnosed in women with high 
mortality rate. This cancer is usually asymptomatic 
and often diagnosed late in the disease process [63]. 
Unfortunately, there are no specific markers for early 
diagnosis. Lim R et al analysed NGAL by IHC in a total 
of 59 ovarian tissues including normal, benign, borderline 
and malignant (grades 1, 2 and 3). NGAL expression was 
weak or moderate in benign tissues. Both borderline and 
grade 1 tumors displayed the highest amount of NGAL 
expression with moderate to strong staining, whereas 
in grade 2 and 3 tumors, the extent of staining was 
significantly less (p < 0.01) and staining intensity was 
weak to moderate. Additionally, the authors analyzed, by 
ELISA, NGAL levels in 62 serum samples from normal 
individuals and ovarian cancer patients (grade 1). The 
NGAL concentration was 2 and 2.6-fold higher in patients 
with benign tumors and cancer patients (grade 1) [19]. 
In line with results provided by Lim et al, all datasets 
here examined showed an upregulation of NGAL in 
ovarian cancer samples, with a range from 3 to 6 fold. 
Furthermore, the analysis of both Bittner and Anglesio 
datasets (Ref. in Table 2) revealed a significant reduction 
of NGAL mRNA levels in metastatic disease (see Table 
2). In the same study, Lim and collaborators analyzed 
NGAL in ovarian cancer cell lines treated with epidermal 
growth factor (EGF) indicating that NGAL expression was 
downregulated in ovarian cancer cell lines undergoing the 
epithelial to mesenchymal transition (EMT) induced by 
EGF. Downregulation of NGAL expression correlated with 
the upregulation of vimentin, enhanced cell dispersion and 
downregulation of E-cadherin expression, some of the 
hallmarks of EMT. These data indicate that NGAL may be 
a good marker to monitor transformation of benign lesions 
to premalignant and malignant ovarian tumors and that the 
molecule may be involved in the progression of epithelial 
ovarian malignancies [19].
NGAL, as well as other proteins, was shown 
to be regulated in ovarian cancer cell lines by 17 
beta-estradiolestrogen [64]. More recently Cho et al. 
described the upregulation of NGAL in a panel of 54 
ovarian cancers, 15 borderline and 53 benign ovarian 
tumors, and 90 healthy controls by real time PCR and 
immunohystochemical analysis. NGAL levels were 
significantly higher in ovarian tissues and particularly in 
well-differentiated tumors. Similar results were obtained 
by analyzing NGAL serum levels from ovarian cancer 
patients showing highest levels in differentiated cancer 
[65]. Notably, according to previous data, the results 
of the present study show that 91,2% of ovarian cases 
displayed NGAL transcripts above the 75th percentile of 
the “normal” values, while 0.4% below the 25th percentile. 
Similar trend was obtained for the IHC analyses. While 
transcript levels of NGAL were significantly lower in 
metastatic setting compared to primary tumor.       
Pancreatic cancer
Pancreatic cancer (PaCa) is the fifth leading cause of 
cancer death in both men and women [66]. Early detection 
of this disease is not possible in spite of significant 
diagnostic tools. The effective therapy, surgery, is limited 
to about 25% of the cases and often is unable to prevent 
cancer recurrence in these patients [67]. Much remains to 
be understood about the natural course and biology of this 
disease.
Using microarray analysis, many laboratories have 
reported the differential expression of several novel 
genes, including that of NGAL, associated with the 
progression of pancreatic cancer [68-70]. Moniaux et al 
detected NGAL levels by immunohistochemistry on tissue 
samples from normal patients, pancreatitis, and pancreatic 
adenocarcinoma patients. Their results revealed higher 
levels in pancreatic adenocarcinoma than in normal and 
pancreatitis samples [71]. These findings are in agreement 
with the results of the present study in which we observe a 
constant upregulation of NGAL at both mRNA and protein 
expression levels in pancreatic adenocarcinoma samples 
vs normal tissues. Moniaux et al also evaluated NGAL 
levels in pancreatic cancer cell lines with varying grades 
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of differentiation documenting a positivity for NGAL 
expression in both well and moderately differentiated 
cells. In contrast, NGAL expression was uniformly 
negative in poorly differentiated adenocarcinoma. Further, 
they examined NGAL levels in serum samples. They 
used ELISA to detect NGAL. The authors concluded 
that NGAL was fairly accurate in distinguishing between 
pancreatic cancers and non-cancer cases. In conclusion, 
NGAL is highly expressed in early pancreatic dysplastic 
lesions, suggesting a possible role as an early diagnostic 
marker for pancreatic cancer [71]. 
NGAL is also detected in bile and may be useful as 
a novel biomarker to distinguish benign from malignant 
biliary obstruction [72].
The biological roles of NGAL in pancreatic 
adenocarcinoma have been studied both in vitro and in 
vivo by Tong et al [17]. The authors transfected PaCa 
cells with NGAL and demonstrated no effects on cell 
viability or sensitivity to chemotherapy, but decreases in 
cell adhesion, invasion and angiogenesis was observed 
both in vitro and in vivo. The negative effects on tumor 
progression and metastasis were due to alteration of FAK 
phosphorylation and decrease of VEGF production [17]. 
We can gather from this study that modulation of NGAL 
activity could control PaCa angiogenesis and metastasis. 
Prostate cancer 
According to the exclusion criteria designed for 
the purpose of our present study, no differences were 
identified between prostate cancer tissue and the normal 
counterparts. Similarly, IHC evaluation did not display any 
differences between normal and tumor. While, significant 
differences were observed in metastatic disease of prostate 
cancer when compared with primary tumors as NGAL 
transcripts were lower in metastatic setting compared 
to primary tumor. However, in vitro studies showed 
that NGAL plays a significant role in the progression of 
prostate cancer by regulating MMP2 and MMP-9 [73]. 
Therefore further studies are needed to better clarify the 
role of NGAL in prostate cancer, as until now conflicting 
results have been generated between “in silico” and “in 
vitro” data. 
Renal tumor
The incidence of renal cell carcinoma (RCC) is 
growing [74]. Most of the patients initially diagnosed 
with localized disease are cured by surgery, but over 
30% of them die from relapse. The molecular basis of a 
great diversity in clinical behavior of RCC is still unclear 
and makes it a target to investigate the nature of these 
heterogeneities [75].
A recent immunohistochemical study on a set of 30 
surgically-resected renal tumors revealed that NGAL is 
expressed in several histotypes of renal tumors especially 
in papillary and chromphobe histotypes. NGAL expression 
is highest in the higher histological grade of papillary and 
clear cell RCC and in its peritoneal metastasis [76].The 
authors suggested that the upregualtion of NGAL in the 
above-mentioned tumor histotypes could be related to an 
increased requirement of iron uptake and could justify 
the use of iron chelators for renal cancer therapies. In 
agreement, our analysis revealed an upregulation of 
NGAL in RCC. Conversely, IHC evaluation did not show 
any immunostaining for NGAL. It was further shown 
that NGAL, as detected by ELISA, had predict value for 
progression free survival in RCC patients treated with 
sunitinib malate [77]. While, most recent data conducted 
by Di Carlo does not reach any conclusive results on the 
usefulness of NGAL as a diagnostic marker [78].
Thyroid cancer
Our data show that transcript levels of NGAL are 
higher in tumor thyroid cancer (papillary carcinoma) when 
compared with normal counterpart. In fact, 83.7% of case 
displayed NGAL transcripts above the 75th percentile of 
“normal” values, while 6.1% of cases showed mRNA 
levels of NGAL below the 25th percentile (Figure 3, Panel 
K). In contrast, no protein expression was detect by IHC 
(Human Protein Atlas web site). According to mRNA 
expression data, previous studies showed that NGAL is 
overexpressed in thyroid cancer [79-81]. 
Hematological malignancies 
Different then for solid tumor, NGAL expression in 
hematological malignancies displays a very homogeneous 
behavior: in fact, all the datasets that reach the levels of 
significance p<0.01 exhibit an uniform downregulation of 
NGAL compared to controls. Datasets analyzed included 
myeloma and leukemias (ALL, acute lymphoblastic 
leukemia; AML, acute myeloid leukemia, CLL; chronic 
lymphocytic leukemia). Accordingly, recent data show that 
highest mRNA NGAL levels were associated with better 
prognosis in AML [82]. According to the exclusion criteria 
designed for the purpose of the present study, no data on 
chronic myeloid leukemia (CML) were generated by 
computational analysis. However, NGAL was identified 
in an expression profiling study on CML cells. In this 
work, the authors analysed gene expression profiles of 
cancer cells from 27 patients using a cDNA microarray. 
Among the 150 genes up-regulated, they observed an 
increase of NGAL mRNA levels in CML patients [83]. 
Subsequently, Villalva C et al have performed RT-PCR 
for NGAL expression in a large cohort of CML patients. 
Their results indicate that NGAL is expressed in parallel 
with the BCR-ABL oncoprotein at the early stage of 
leukemia process and it is secreted at high levels in these 
Oncotarget1588www.impactjournals.com/oncotarget
patients. The authors have excluded the possibility that 
the large increase of NGAL expression in CML patients 
at diagnosis resulted from the presence of circulating 
myelocytes in blood, which constitutively secrete NGAL 
protein during maturation [84]. Leng et al have proposed 
two activities associated with NGAL in a mouse model 
of CML tumorigenesis. On the one hand, NGAL induces 
apoptosis of normal hematopoietic cells resulting in the 
replacement of  these with leukemic cells and on the other 
NGAL facilitates tissue invasion through stabilization of 
MMP-9 activity [85].
CONCLUSION
Our computational analysis suggest an active role 
of NGAL in early stages of tumor development, reason 
that many authors proposed NGAL as a diagnostic and 
prognostic marker. While a decrease of NGAL expression 
in metastatic samples was detected when compared to 
matched primary tumors. This observation suggests a 
common inactivation pathway of NGAL gene during 
distant tumor dissemination and leads us to venture the 
hypothesis that NGAL could play a protective role in 
metastatic development. 
In particular, the tumors showing higher NGAL 
expression (expression levels greater than the 75th 
percentile of “normal” samples) were: ovarian (91.2%), 
thyroid (83.7%), liver (68.8%), colon (66.3%), kidney 
(64.7%), lung (63.1%), pancreas (60.2%) and bladder 
(50.5%). While, the percentages of tumor cases 
showing NGAL transcripts below the 25th percentile of 
“normal” values were almost 100% of all hematological 
malignancies and 94.6% of head and neck cancer, 71.4% 
of esophagus cancer and 59.4% of cervical carcinoma. 
These data suggest that NGAL is a candidate marker for 
tumor growth in a fraction of solid tumor and a favorable 
prognostic factor for the remaining cancer types showing 
lower levels of NGAL transcript levels. 
The analysis of previous studies revealed a lack of 
information about NGAL correlation with metastasis and 
almost completely consistent with the bionformatic data. 
The present study deepens the knowledge of the molecular 
mechanisms sustaining NGAL expression in tumor cells 
and its effects on cancer metastatic behavior. Further 
investigations are required to elucidate the function of 
NGAL in tumor development and metastatic processes.
MATERIAL AND METHODS
ONCOMINE software (https://www.oncomine.com) 
was used (December 2013) to compare mRNA expression 
levels between normal tissue versus tumor and primary 
tumor versus metastatic, and in both cases evaluated on 
biopsy samples. Statistical analysis of the differences in 
NGAL mRNA expression between the abovementioned 
sets of samples was accomplished through use of 
ONCOMINE algorithms. Only datasets generated by 
Affymetrix U133 platform were considered for the present 
analysis. Of note, this platform used the “212531_at” 
NGAL probe set. Datasets showing different expression 
analysis between normal and tumor tissues with statistical 
significance less than 0.01 (by t-test) and fold change ≤ -2 
or ≥ 2 were included; while, those showing a differential 
expression between primary tumor and metastasis with 
a statistic significance less than 0.05 (by t-test) and fold 
change ≤ -1.5 or ≥ 1.5 were considered. According to 
these criteria, 38 datasets were used for the purpose of the 
study. Of these, 29 were used for the comparative analysis 
between normal and tumor tissues [86-111]; while, 9 were 
used to analyze the differences between primary tumor 
and metastasis [112-118]. Fold change was calculated 
to evaluate the changes in gene expression between the 
groups of samples included in this analysis. Properties of 
the datasets are presented in Tables 1 and 2. 
To assess the distribution of NGAL transcript 
levels among cancer types and normal samples,  mRNA 
expression levels from Oncomine analysis were 
normalized using an housekeeping gene in each dataset 
and then merged together. The choice of the housekeeping 
gene was made on the basis of the homogenous mRNA 
levels distribution. When more than one probset was 
available, the mean value of the same housekeeping gene 
was used for the normalization. To define the “normal 
range” of expression we calculated the 25th and the 75th 
percentile of NGAL transcript levels in normal samples 
for each tumor type. Accordingly, the percentage of 
tumor samples showing NGAL levels outside the defined 
“normal range” was calculated. 
NGAL protein expression was performed by 
analyzing the web site of Human Protein Atlas (http://
www.proteinatlas.org/). As indicate in the web site, 
expression of NGAL for each tumor type was evaluated 
as strong, moderate, weak and negative immunostaining. 
The Sigma-Aldrich HPA002695 NGAL antibody was 
employed for this analysis.  
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